Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 46
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
80% more call options, than puts
Call options by funds: $296M | Put options by funds: $164M
15% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 126
6% less first-time investments, than exits
New positions opened: 81 | Existing positions closed: 86
1.09% less ownership
Funds ownership: 74.59% [Q3] → 73.51% (-1.09%) [Q4]
3% less funds holding
Funds holding: 418 [Q3] → 404 (-14) [Q4]
36% less capital invested
Capital invested by funds: $5.17B [Q3] → $3.3B (-$1.87B) [Q4]
75% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 2 (-6) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
6%
upside
Avg. target
$83
191%
upside
High target
$104
266%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Cantor Fitzgerald Steven Seedhouse 0% 1-year accuracy 0 / 8 met price target | 266%upside $104 | Overweight Initiated | 28 Apr 2025 |
Truist Securities Joon Lee 38% 1-year accuracy 15 / 40 met price target | 164%upside $75 | Buy Reiterated | 28 Apr 2025 |
Morgan Stanley Michael Ulz 32% 1-year accuracy 6 / 19 met price target | 259%upside $102 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 77 / 387 met price target | 259%upside $102 | Buy Reiterated | 24 Apr 2025 |
Goldman Sachs Richard Law 45% 1-year accuracy 5 / 11 met price target | 6%upside $30 | Neutral Initiated | 8 Apr 2025 |
Financial journalist opinion
Based on 22 articles about VKTX published over the past 30 days
Positive
The Motley Fool
1 hour ago
Why Viking Therapeutics Stock Bumped 3% Higher Today
A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (VKTX 3.61%) stock on Friday, which closed the trading session 3% higher. That figure was well higher than the 0.7% increase of the benchmark S&P 500 index.
Positive
The Motley Fool
3 days ago
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.
Positive
The Motley Fool
5 days ago
3 Monster Stocks in the Making
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
Positive
The Motley Fool
1 week ago
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April.
Positive
The Motley Fool
2 weeks ago
Why Viking Therapeutics Stock Was Victorious This Week
Viking Therapeutics (VKTX 2.85%), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence.
Positive
The Motley Fool
2 weeks ago
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Positive
The Motley Fool
2 weeks ago
Where Will Viking Therapeutics Be in 3 Years?
The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small developer into a mainstream competitor.
Positive
The Motley Fool
2 weeks ago
1 Beaten-Down Stock to Buy and Hold for 10 Years
Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.
Positive
The Motley Fool
2 weeks ago
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.
Positive
The Motley Fool
2 weeks ago
Why Viking Therapeutics Stock Popped Again Today
Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.
Charts implemented using Lightweight Charts™